Showing 7921-7930 of 9734 results for "".
- Arcutis: Phase 1/2b Enrollment Complete for ARQ-252 in Chronic Hand Eczemahttps://practicaldermatology.com/news/arcutis-phase-12b-enrollment-complete-for-arq-252-in-chronic-hand-eczema/2460578/Arcutis Biotherapeutics, Inc. has completed enrollment in the Phase 1/2b studyof its Janus kinase type 1(JAK1) ARQ-252 in adult patients with chronic hand eczema. Arcutis has updated its projected topline data from this trial to mid-2021.
- Beiersdorf Inc. Observes 10 Years of dermMentors Residents of Distinctionhttps://practicaldermatology.com/news/beiersdorf-inc-observes-10-years-of-dermmentors-residents-of-distinction/2460577/As part of the dermMentors™ Resident of Distinction Award™, Beiersdorf Inc. sponsored five top dermatology residents to attend the 16th Annual Coastal Dermatology Symposium, held in a Virtual Format for 2020. The 2020 Residents of Distinction are Shaundra Eichsta
- New from BTL: Emsculpt NEO Launcheshttps://practicaldermatology.com/news/new-from-btl-emsculpt-neo-launches/2460571/The first procedure to combine radio frequency heating and high-intensity focused electromagnetic waves into a single therapy, Emsculpt NEO from BTL, has launched. It is FDA-cleared to eliminate fat cells non-invasively. Emsc
- Eczema Missing Link Found: Researchers ID Protein that Triggers AD by Bacteriahttps://practicaldermatology.com/news/eczema-missing-link-found-researchers-id-protein-that-triggers-ad-by-bacteria/2460567/Second immunoglobulin-binding protein (Sbi) is a unique trigger of eczema by Staphylococcus aureus, according to research in the Journal of Allergy and Clinical Immunology. Sbi induces rapid release of Interleukin-33, a key component of the immune response in childhood ecz
- Coverage Update: Cigna to Cover Excimer Laser Treatment for Vitiligohttps://practicaldermatology.com/news/coverage-update-cigna-to-cover-excimer-laser-treatment-for-vitiligo/2460566/Cigna, a global health services company offering health, pharmacy, dental and Medicare plans to both individuals and businesses covering over 20 million people in the United States, has issued a new medical coverage policy for excimer laser therapy vitiligo. STRATA Skin Sciences, maker of the XTR
- ADCS Acquires Montgomery Dermatology; Catawba Research Enters Partnershiphttps://practicaldermatology.com/news/adcs-acquires-montgomery-dermatology-catawba-research-enters-partnership/2460565/Advanced Dermatology and Cosmetic Surgery (ADCS), the largest dermatology practice in the US, has acquired Dermatology Associates of Montgomery, a leading dermatology practice based in the Southeast. Bundy Group served as exclusive financial advisor to Dr. Steve Maddox, owner of Dermatology
- Optical Coherence Tomography Plus AI Can Quickly and Accurately Monitor Hair Regrowthhttps://practicaldermatology.com/news/optical-coherence-tomography-plus-ai-can-quickly-and-accurately-monitor-hair-regrowth/2460564/Optical coherence tomography plus artificial intelligence methods can accurately and efficiently monitor hair growth therapies, suggests a
- Third RAD Conference Goes Virtual in Decemberhttps://practicaldermatology.com/news/third-rad-conference-goes-virtual-in-december/2460555/With a virtual format, the Third Revolutionizing Atopic Dermatitis (RAD) Conference is slated for December 13-14, 2020. Described by organizers as the first and only global, multidisciplinary conference dedicated to the discussion of evaluation and treatment options for atopi
- Cynosure Launches FlexSure in US and Canadahttps://practicaldermatology.com/news/cynosure-launches-flexsure-device/2460552/Cynosure is launching FlexSure, the latest addition to the TempSure platform, in the US and Canada. FlexSure is a wrappable radiofrequency (RF) applicator for hands-free treatment on all patients and all skin types. With peel-and-sti
- Zilxi from Vyne Therapeutics Now Availablehttps://practicaldermatology.com/news/zilxi-from-vyne-therapeutics-now-available/2460551/Zilxi™ (minocycline) topical foam, 1.5% is now available by prescription for the treatment of inflammatory lesions of rosacea in adults. Zilxi, from Vyne Therapeutics, Inc. is the first minocycline product of any form to be approved by the FDA for use in rosacea, a diverse skin co